This trial uses DSC-MRI to measure rCBV to determine response to bevacizumab in patients with recurrent glioblastoma. DSC-MRI may help to evaluate changes in cancer blood vessels.
2 Primary · 4 Secondary · Reporting Duration: Up to 5 years
146 Total Participants · 1 Treatment Group
Primary Treatment: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging · No Placebo Group · N/A
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: